A prospective study comparing patient-reported outcomes in Crohn's disease.

"Conflicts of interest G.D.H. has served as advisor for Abbvie, Ablynx, Actogenix, Amakem, Amgen, AM Pharma, AstraZeneca, Avaxia, Bristol Meiers Squibb, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Elan, Ferring, DrFALK Pharma, Centocor/Jansen Biologics, Engene, Ferring, Galapagos, Gilead, Glaxo Smith Kline, Hospira, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novonordisk, Otsuka, Pfizer, Protein Design Laboratories, Prometheus laboratories/Nestle, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, UCB, Versant and Vifor and received speaker fees from Abbvie, Ferring, Jansen Biologics, Merck Sharp Dome, Mundipharma, Norgine, Shire, Takeda, Tillotts, UCB and Vifor. C.Y.P. received grant support from Takeda, speaker’s fee from Takeda, Abbvie, and Dr Falk Pharma, and consultancy fee from Takeda. M.L. received speaker fees from Abbvie, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts and Tramedico, and has received grant support from AbbVie, Merck Sharp & Dohme, Achmea healthcare and ZonMW. G.B. is an employee of GlaxoSmithKline. There are no conflicts of interest for the remaining authors."